Company:  VERTEX PHARMACEUTICALS IN ... (VRTX)
Form Type:  10-Q
Filing Date:  7/30/2021 
CIK:  0000875320 
Address:  50 NORTHERN AVENUE 
City, State, Zip:  BOSTON, Massachusetts 02210 
Telephone:  (617) 341-6393 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$299.51  
Change: 
-2.51 (-0.83%)  
Trade Time: 
01:40 PM EST  
Market Cap: 
$76.81B
Trade VRTX now with 

© 2022  
Description of Business
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We have multiple approved medicines that treat the underlying cause of cystic fibrosis, or CF, a life-threatening genetic disease, and we have several ongoing clinical and research programs to advance and extend treatment of CF. Beyond CF, we have a pipeline of investigational therapies in other serious diseases where we are leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Marketed Products Our goal in CF is to develop treatment regimens that will provide benefits to all people with CF and will enhance the benefits currently provided to people taking our medicines.
Register and access this filing in:     
  FORM 10-Q
    Part I. Financial Information
      Item 1. Financial Statements
        INCOME STATEMENT
        BALANCE SHEET
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements (unaudited)
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II. Other Information
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 10.2
  EXHIBIT 10.3
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    SECTION 906 CEO/CFO CERTIFICATION